Feline Gammaherpesvirus: Veterinary Reference

Overview and Taxonomy of Feline Gammaherpesvirus: Veterinary Reference

Taxonomic Classification and Genomic Architecture

Felis catus gammaherpesvirus 1 (FcaGHV-1) occupies a distinct position within the subfamily Gammaherpesvirinae of the family Herpesviridae, a lineage characterized by its lymphotropic nature and capacity for long-term latency within host B lymphocytes and other lymphoid cells. Unlike the more extensively studied feline alphaherpesvirus (FHV-1), which predominantly targets epithelial and neuronal tissues causing acute respiratory and ocular disease [1], gammaherpesviruses are biologically distinguished by their ability to establish lifelong infections with periodic reactivation, often in the context of immunosuppression. The taxonomic assignment of FcaGHV-1 was initially based on phylogenetic analyses of conserved viral genes; sequences derived from Turkish isolates, when compared with a reference strain from Japan (GenBank accession LC437925), formed a distinct subclade within the gammaherpesvirus tree, confirming its species-level designation [3]. Genomically, FcaGHV-1 shares synteny with other mammalian gammaherpesviruses, including the prototypical human gammaherpesviruses Epstein–Barr virus (HHV-4) and Kaposi’s sarcoma-associated herpesvirus (HHV-8), although its precise open reading frame repertoire remains incompletely annotated. The viral genome is a linear double-stranded DNA molecule, approximately 130–150 kbp in length, enclosed within an icosahedral capsid and a lipid envelope bearing glycoprotein spikes essential for host cell entry and immune evasion. The thymidine kinase and glycoprotein B/D homologs, commonly used as phylogenetic markers in herpesviruses [1], have been partially characterized in FcaGHV-1 and show moderate homology to those of other felid gammaherpesviruses, suggesting a coevolutionary relationship with the host species.

Epidemiology and Host Range

The discovery of FcaGHV-1 is relatively recent, with the first molecular evidence emerging from domestic cat populations in Japan and subsequently in Europe and the Middle East. Prevalence data remain sparse, but available studies indicate that FcaGHV-1 circulates globally. In a Turkish cohort of 45 cats presenting with ocular disorders, 2 animals (4.4%) tested positive for FcaGHV-1 DNA by PCR and sequencing, both of which were also co-infected with feline immunodeficiency virus (FIV) [3]. This co-infection rate is striking and aligns with findings from an Australian study examining the impact of retroviral co-infections: FcaGHV-1 DNAemia was significantly more frequent in cats co-infected with FIV and feline leukemia virus (FeLV) compared with retrovirus-uninfected controls [4]. The prevalence of FcaGHV-1 in the general feline population is likely underestimated because many infections are subclinical and routine diagnostic panels do not yet include FcaGHV-1-specific assays. The virus has been detected in whole blood, suggesting a cell-associated viremia typical of gammaherpesviruses, and transmission is presumed to occur via direct contact with infected saliva or other bodily fluids, given the known shedding patterns of related viruses. Unlike FHV-1, which can survive for short periods in the environment, FcaGHV-1 is enveloped and labile outside the host, necessitating close contact for effective spread. Age, sex, and breed associations have not been systematically evaluated, but one report noted that male cats appear to be overrepresented in FcaGHV-1-positive cohorts, possibly reflecting behavioral factors such as fighting and territorial aggression that facilitate transmission via bite wounds [3]. The virus has also been reported in wild felids, although cross-species transmission dynamics remain poorly defined.

Pathogenesis and Clinical Significance

The pathogenic role of FcaGHV-1 in domestic cats is not yet fully elucidated, but accumulating evidence points to its potential as a co-pathogen in retrovirus-infected individuals. Experimental and observational data have demonstrated that FIV-infected cats are at increased risk for FcaGHV-1 DNAemia and consistently harbor higher viral loads compared with FIV-uninfected controls [4]. This interaction mirrors the well-established synergy between human gammaherpesviruses (e.g., HHV-8) and human immunodeficiency virus (HIV), where co-infection dramatically increases the risk of virus-associated malignancies such as Kaposi’s sarcoma. In the feline model, FcaGHV-1 may similarly act as a trigger for lymphoproliferative disorders, although definitive proof remains lacking. Notably, a study comparing therapeutically immunosuppressed cats, FeLV-monoinfected cats, and FIV/FeLV-co-infected animals found that only the co-infected group exhibited a significantly higher frequency of FcaGHV-1 DNAemia, suggesting that the immunological milieu created by dual retroviral infection, characterized by profound CD4+ T-cell depletion and impaired antiviral immunity, provides a permissive environment for gammaherpesvirus reactivation [4]. The same study reported no difference in FcaGHV-1 DNAemia between cats receiving immunosuppressive therapy (e.g., corticosteroids or cyclosporine) and matched controls, indicating that the risk is not simply a function of generalized immunosuppression but may require specific defects in gammaherpesvirus-specific immune surveillance, such as loss of cytotoxic T-cell function, which is a hallmark of FIV infection.

Clinically, the direct manifestations of FcaGHV-1 infection are subtle. In the Turkish ocular survey, no significant association was found between FcaGHV-1 presence and specific ophthalmic lesions, although the small sample size precludes definitive conclusions [3]. Other potential associations, such as with stomatitis, lymphoma, or febrile episodes, have been anecdotally reported but require rigorous case-control studies. The virus’s tropism for lymphoid tissue suggests that chronic infection could contribute to immune dysregulation, possibly exacerbating the immunodeficiency already induced by FIV or FeLV. Furthermore, the observation that FcaGHV-1 DNA loads are elevated in FIV-positive cats raises the possibility that the virus may serve as a surrogate marker for retroviral disease progression, analogous to CMV viral load monitoring in HIV-positive humans.

Diagnostic Approaches and Molecular Detection

Detection of FcaGHV-1 currently relies exclusively on molecular techniques, as no validated serological assays are commercially available. Quantitative real-time PCR (qPCR) targeting conserved regions of the viral genome, often the DNA polymerase or glycoprotein B genes, has been used in research settings to quantify viral DNA in whole blood, plasma, or tissue biopsies [4]. In the Turkish study, conventional PCR followed by sequencing of amplicons was employed to confirm FcaGHV-1 identity and to perform phylogenetic analysis [3]. The limit of detection of these in-house assays is typically in the range of 10–100 copies per reaction, but standardization across laboratories is lacking. Given the low prevalence in healthy populations, screening for FcaGHV-1 is not currently recommended as a routine test; however, in cats with unexplained lymphocytosis, persistent fever, or retroviral co-infection, testing may be warranted as part of a comprehensive infectious disease workup. One diagnostic challenge is the potential for intermittent DNAemia, as gammaherpesviruses can enter a latent state during which viral DNA is present at very low levels or only in lymphoid tissue. Therefore, a single negative whole-blood PCR does not rule out infection, and repeat testing or analysis of lymph node aspirates may be necessary. The advent of multiplex platforms, such as the barcoded magnetic bead–based immunoassays described for FeLV/FIV [2], could theoretically be adapted to include FcaGHV-1 antigen detection, but such assays would first require identification of suitable viral antigens and extensive validation. Until then, PCR remains the gold standard.

Comparative and One Health Perspectives

FcaGHV-1 occupies a valuable niche in comparative virology, offering a naturally occurring small animal model for studying gammaherpesvirus pathogenesis, latency, and reactivation in the context of retroviral immunosuppression. The parallels with human coinfections are compelling: both FIV and HIV induce progressive immune dysfunction, and both are associated with increased gammaherpesvirus loads and disease. The feline model has been instrumental in understanding the mechanisms by which gammaherpesviruses evade immune clearance and drive lymphomagenesis. For instance, the recombinant canarypox virus expressing feline interleukin-2 (ALVAC-fIL2), originally developed as an immunomodulator for injection-site sarcomas [5], has also been investigated in the context of gammaherpesvirus immunology, though direct applications to FcaGHV-1 are nascent. From a regulatory perspective, the World Organisation for Animal Health (WOAH) does not currently list FcaGHV-1 as a notifiable disease, reflecting its low perceived impact on feline health at the population level. However, as the veterinary community becomes more aware of this emerging pathogen, and as the global cat population continues to grow, surveillance efforts may need to expand. The ongoing refinement of the domestic cat reference genome [6] will facilitate functional genomics studies of FcaGHV-1, enabling identification of viral oncogenes and deciphering of host–virus interactions that may inform both feline and human medicine. Ultimately, FcaGHV-1 represents a compelling example of a “hidden” virus whose clinical significance is only beginning to emerge, and whose study promises to deepen our understanding of gammaherpesvirus biology within a One Health framework.

Molecular Pathogenesis of Feline Gammaherpesvirus Infection

Virological Architecture and Genomic Organization

Felis catus gammaherpesvirus 1 (FcaGHV-1) represents a recently characterized member of the Gammaherpesvirinae subfamily, a lineage of lymphotropic DNA viruses that establish lifelong latency and are increasingly recognized for their oncogenic potential and capacity for immune modulation. The genomic architecture of FcaGHV-1 mirrors that of other gammaherpesviruses, including the human pathogens Epstein-Barr virus (EBV) and Kaposi’s sarcoma-associated herpesvirus (KSHV), as well as the murine gammaherpesvirus 68 (MHV-68), a well-established model for studying gammaherpesvirus pathogenesis. The FcaGHV-1 genome is a linear double-stranded DNA molecule, approximately 130–140 kilobase pairs in length, characterized by a central unique region flanked by variable numbers of terminal repeats. This structural organization is critical for viral genome circularization during latency, a process that facilitates episomal persistence within the host cell nucleus. The genome encodes a core set of conserved herpesvirus genes involved in DNA replication, capsid assembly, and immune evasion, alongside unique open reading frames (ORFs) that likely contribute to its specific tropism and pathogenic profile in feline hosts.

Comparative genomic analyses have revealed that FcaGHV-1 clusters phylogenetically with other gammaherpesviruses of carnivores, including the mustelid gammaherpesvirus 1 and the canine gammaherpesvirus. Sequence homology studies, particularly of the glycoprotein B (gB) and DNA polymerase genes, place FcaGHV-1 within the Rhadinovirus genus, a group characterized by their association with lymphoproliferative disorders and malignancies. The virus encodes several homologs of cellular genes implicated in cell cycle regulation, apoptosis inhibition, and signal transduction, a hallmark of gammaherpesvirus pathogenesis. These include viral homologs of Bcl-2 (vBcl-2), which inhibit apoptosis, and viral cyclins (v-cyclins), which drive cell cycle progression. The presence of these pirated cellular genes underscores the virus’s sophisticated strategy for manipulating host cellular machinery to promote viral persistence and, under permissive conditions, cellular transformation.

Cellular Tropism and Establishment of Latency

The primary cellular targets of FcaGHV-1 are B lymphocytes, a defining characteristic shared with EBV and other gammaherpesviruses. The virus gains entry into B cells through a multi-step process involving initial attachment to cell surface heparan sulfate proteoglycans, followed by high-affinity binding to a specific entry receptor. While the cognate receptor for FcaGHV-1 has not been definitively identified, structural and functional homology with other gammaherpesviruses suggests the involvement of a member of the immunoglobulin superfamily or a complement receptor, such as CD21 or MHC class II molecules, which serve as entry portals for EBV. Following receptor-mediated endocytosis or direct fusion at the plasma membrane, the viral capsid is transported to the nuclear pore, where the viral genome is released into the nucleoplasm. Once inside the nucleus, the linear genome circularizes to form an episome, a stable extrachromosomal element that is tethered to host chromosomes during cell division via the viral genome maintenance protein, likely a homolog of EBNA1 or LANA (latency-associated nuclear antigen).

The establishment of latency is a cornerstone of gammaherpesvirus biology and is exquisitely regulated by a cascade of viral gene expression programs. Upon initial infection, a limited set of latency-associated genes is expressed, including those encoding the v-cyclin, vBcl-2, and a latency-associated nuclear antigen. These proteins collectively orchestrate the survival and proliferation of the infected B cell. The v-cyclin drives the cell cycle from G1 into S phase, promoting cellular proliferation, while vBcl-2 protects the infected cell from apoptosis that would otherwise be triggered by unchecked cell cycle entry. This proliferative signal is essential for expanding the pool of latently infected cells, a process that occurs within lymphoid tissues, particularly the tonsils, lymph nodes, and spleen. The latent viral genome is replicated once per cell cycle by the host DNA polymerase, ensuring that each daughter cell inherits a copy of the viral episome. This lifelong persistence in the B cell compartment is the foundation for the virus’s ability to reactivate and cause disease under conditions of immunosuppression.

Molecular Mechanisms of Immune Evasion

FcaGHV-1, like all gammaherpesviruses, has evolved a formidable arsenal of immune evasion strategies designed to subvert both innate and adaptive immune responses. These mechanisms are critical for establishing and maintaining lifelong latency and for facilitating viral reactivation. The virus encodes several proteins that interfere with antigen presentation, cytokine signaling, and the activation of cytotoxic immune cells. One of the most well-characterized evasion strategies involves the downregulation of major histocompatibility complex (MHC) class I molecules on the surface of infected cells. By reducing MHC class I expression, the virus limits the ability of cytotoxic T lymphocytes (CTLs) to recognize and eliminate infected cells. This is achieved through viral proteins that retain MHC class I molecules in the endoplasmic reticulum or target them for proteasomal degradation, a mechanism analogous to that employed by KSHV and MHV-68.

Furthermore, FcaGHV-1 likely encodes homologs of viral chemokine-binding proteins (vCKBPs) and viral interleukin-10 (vIL-10), which modulate the inflammatory microenvironment. vCKBPs bind to host chemokines with high affinity, preventing their interaction with cellular receptors and thereby disrupting the recruitment of immune cells to sites of infection. vIL-10, a homolog of the anti-inflammatory cytokine IL-10, suppresses the activation of macrophages and dendritic cells and inhibits the production of pro-inflammatory cytokines such as IL-12 and TNF-α. This creates an immunosuppressive milieu that favors viral persistence. The virus also interferes with the interferon (IFN) signaling pathway, a critical component of the innate antiviral response. By blocking the phosphorylation and nuclear translocation of STAT transcription factors, FcaGHV-1 can effectively neutralize the antiviral effects of type I and type II interferons, allowing viral replication to proceed unimpeded during lytic reactivation.

Lytic Reactivation and Cytopathic Effects

While latency is the default program for FcaGHV-1, periodic reactivation into the lytic cycle is essential for viral transmission and, under certain circumstances, contributes to pathogenesis. Reactivation is triggered by a variety of stimuli, including cellular stress, inflammation, and, most notably, immunosuppression. The switch from latency to lytic replication is governed by the expression of the viral immediate-early (IE) gene, which acts as a master regulator of the lytic cascade. The IE protein transactivates the expression of early genes, which encode enzymes required for viral DNA replication, including the viral DNA polymerase, thymidine kinase, and helicase-primase complex. Following genome replication, late genes encoding structural proteins, such as capsid proteins and glycoproteins, are expressed, leading to the assembly of progeny virions.

The lytic cycle is highly cytopathic, resulting in the destruction of the infected B cell. The release of newly synthesized virions can then infect adjacent B cells or be shed into bodily secretions, facilitating horizontal transmission. The clinical consequences of lytic reactivation are most pronounced in immunocompromised hosts. In cats co-infected with feline immunodeficiency virus (FIV) or feline leukemia virus (FeLV), the frequency of FcaGHV-1 DNAemia is significantly elevated, and viral loads are substantially higher compared to retrovirus-uninfected cats [4]. This observation is consistent with the role of gammaherpesviruses as major co-pathogens in HIV-infected humans, where EBV and KSHV reactivation leads to lymphomas and Kaposi’s sarcoma, respectively. The molecular basis for this enhanced reactivation in retrovirus-infected cats is multifactorial, involving the depletion of CD4+ T cells, impaired CTL function, and the chronic inflammatory state induced by FIV and FeLV. Interestingly, therapeutic immunosuppression with corticosteroids or cyclosporine does not appear to increase the risk of FcaGHV-1 DNAemia to the same extent as retroviral infection, suggesting that the specific immune deficits induced by FIV and FeLV are particularly permissive for gammaherpesvirus reactivation [4].

Association with Neoplastic Transformation

The oncogenic potential of gammaherpesviruses is well established, with EBV and KSHV being classified as Group 1 carcinogens by the International Agency for Research on Cancer (IARC), an agency of the World Health Organization (WHO). While a definitive causal link between FcaGHV-1 and feline lymphoma has not yet been established, accumulating evidence points to a plausible role in lymphomagenesis. The virus’s tropism for B cells, its ability to drive B cell proliferation through v-cyclin and vBcl-2 expression, and its capacity to establish lifelong latency all align with the hallmarks of a tumor virus. The v-cyclin encoded by FcaGHV-1 is a potent driver of cell cycle progression, and its constitutive expression in latently infected B cells can lead to genomic instability and the accumulation of secondary mutations. Furthermore, the inhibition of apoptosis by vBcl-2 allows cells with DNA damage to survive, creating a permissive environment for malignant transformation.

The epidemiological association between FcaGHV-1 infection and lymphoma is supported by studies demonstrating a higher prevalence of viral DNA in lymphoma tissues compared to non-lymphoid tissues. However, the presence of the virus in a subset of healthy cats indicates that additional cofactors, such as genetic predisposition, chronic inflammation, or co-infection with other pathogens, are required for tumor development. The molecular pathways involved in FcaGHV-1-mediated transformation are likely to overlap with those of other gammaherpesviruses. For instance, the viral latency protein may activate the NF-κB and PI3K/Akt signaling pathways, which promote cell survival and proliferation. Additionally, the virus may induce epigenetic alterations, such as DNA methylation and histone modification, that silence tumor suppressor genes. The study of FcaGHV-1 in feline lymphoma offers a valuable comparative model for understanding the role of gammaherpesviruses in human B cell malignancies, particularly in the context of HIV-associated lymphomas.

Co-infection Dynamics and Synergistic Pathogenesis

The interplay between FcaGHV-1 and other feline pathogens, particularly FIV and FeLV, is a critical area of investigation with implications for both veterinary and human medicine. As noted, FIV-infected cats consistently harbor higher FcaGHV-1 loads and are at increased risk of DNAemia [4]. This synergistic interaction is bidirectional: FIV-induced immunosuppression facilitates FcaGHV-1 reactivation, while FcaGHV-1 infection may, in turn, exacerbate FIV pathogenesis by further dysregulating the immune system. Gammaherpesviruses are known to modulate the expression of cytokines and chemokines, potentially altering the balance of Th1 and Th2 responses and accelerating the progression of immunodeficiency. In the context of FeLV co-infection, the risk of FcaGHV-1 DNAemia is similarly elevated, particularly in cats co-infected with both FIV and FeLV [4]. This triple co-infection scenario likely represents a state of profound immune dysregulation, where the host’s ability to control any of the three viruses is severely compromised.

The detection of FcaGHV-1 in cats with ocular disorders has also been reported, although a direct causal relationship has not been established [3]. In a study of cats in Turkey, FcaGHV-1 DNA was detected in 4.4% of cats with ocular disease, with co-infection with FIV noted in both positive cases [3]. This finding raises the possibility that FcaGHV-1 may contribute to ocular pathology, either through direct viral cytopathic effects or through immune-mediated mechanisms. The virus’s ability to establish latency in lymphoid tissues associated with the ocular mucosa, such as the conjunctival-associated lymphoid tissue (CALT), could provide a reservoir for reactivation and local inflammation. Further research is needed to determine whether FcaGHV-1 is a genuine ocular pathogen or an incidental bystander in cats with pre-existing ocular disease.

Comparative and Translational Implications

The study of FcaGHV-1 pathogenesis is not only relevant to feline health but also offers a powerful comparative model for understanding human gammaherpesvirus infections. The World Organisation for Animal Health (WOAH) recognizes the importance of studying animal herpesviruses as models for human disease, and the cat provides a unique opportunity to investigate the natural history of a gammaherpesvirus in its native host. The similarities between FcaGHV-1 and EBV/KSHV in terms of genomic organization, cellular tropism, and immune evasion strategies make the feline system an attractive platform for testing novel antiviral therapies and vaccines. For example, the efficacy of antiviral drugs targeting the viral DNA polymerase, such as acyclovir and ganciclovir, can be evaluated in naturally infected cats, providing preclinical data that may be translatable to human clinical trials.

Furthermore, the role of FcaGHV-1 as a co-pathogen in FIV-infected cats mirrors the relationship between EBV/KSHV and HIV in humans. The feline model allows for the study of gammaherpesvirus reactivation in the context of a well-characterized lentiviral infection, with the advantage of a shorter lifespan and the ability to control environmental variables. The Centers for Disease Control and Prevention (CDC) has highlighted the value of animal models for studying HIV-associated malignancies, and the FIV/FcaGHV-1 co-infection model could yield insights into the mechanisms of virus-driven lymphomagenesis that are directly applicable to human AIDS-related lymphomas. The development of a high-quality reference genome for the domestic cat has further accelerated molecular studies, enabling the use of advanced techniques such as RNA sequencing, chromatin immunoprecipitation (ChIP-seq), and proteomics to dissect the host-virus interaction at an unprecedented level of detail [6].

Epidemiology and Transmission Dynamics of Feline Gammaherpesvirus

Discovery and Global Emergence of FcaGHV-1

The identification of Felis catus gammaherpesvirus 1 (FcaGHV-1) marked a significant milestone in feline virology, expanding the known repertoire of herpesviruses capable of infecting domestic cats. As a member of the Gammaherpesvirinae subfamily, FcaGHV-1 shares phylogenetic and biological characteristics with established human pathogens such as Epstein-Barr virus (EBV) and Kaposi's sarcoma-associated herpesvirus (KSHV), both of which are recognized as oncogenic co-factors in immunocompromised hosts. The emergence of FcaGHV-1 as a subject of veterinary investigation parallels a broader recognition that gammaherpesviruses are ubiquitous in mammalian species and often establish lifelong, latent infections with potential for reactivation under conditions of immune dysregulation. Unlike the well-characterized alphaherpesvirus FHV-1, which is a primary cause of feline upper respiratory disease and ocular pathology, the clinical significance of FcaGHV-1 remains incompletely defined. However, the virus's genetic relatedness to oncogenic gammaherpesviruses in other species has prompted intensive surveillance efforts to determine its prevalence, transmission patterns, and potential role in feline morbidity. The earliest molecular detections of FcaGHV-1 were reported in domestic cat populations across multiple continents, including Asia, Europe, Australia, and North America, suggesting a global distribution that predates modern veterinary awareness. The relatively recent discovery of this pathogen necessitates a critical re-evaluation of the feline virome and its interactions with concurrent infections, particularly retroviruses that compromise host immunity.

Global Prevalence and Population Distribution

Seroprevalence and molecular prevalence studies have revealed that FcaGHV-1 infection is widespread but highly variable across geographic regions and cat populations. In a molecular survey conducted in Turkey, Koç and Bircan (2020) detected FcaGHV-1 DNA in 4.4% (2/45) of cats presenting with ocular disorders, establishing the first evidence of this virus in the Turkish feline population [3]. This prevalence rate is consistent with findings from other initial surveys, which typically report detection rates ranging from 2% to 10% in healthy or clinically ill cats. Importantly, the Turkish study employed PCR-based detection of viral DNA from swab, blood, and biopsy samples, highlighting the virus's potential tropism for multiple tissue compartments. The authors noted that both FcaGHV-1-positive cats in their cohort were also co-infected with FIV, a finding that resonates with subsequent investigations into the synergistic interactions between gammaherpesviruses and lentiviruses [3]. In a more targeted investigation of FcaGHV-1 DNAemia in Australia, McLuckie et al. (2017) utilized quantitative PCR (qPCR) to screen whole blood samples from cats with various immunosuppressive conditions [4]. Their study included retrovirus-infected cats (FIV, FeLV, and FIV/FeLV co-infected), therapeutically immunosuppressed cats receiving glucocorticoids or cyclosporine, and age- and sex-matched controls. Among FIV-monoinfected cats, the frequency of FcaGHV-1 DNAemia was notably elevated compared to retrovirus-free controls, and infected cats consistently harbored higher viral loads. This dose-dependent relationship between FIV infection and FcaGHV-1 replication underscores the critical role of host immune status in modulating gammaherpesvirus latency and reactivation, a paradigm well-established in human HIV–gammaherpesvirus co-infections.

Extrapolating prevalence data from other feline herpesviruses provides useful comparative context. Kim et al. (2024) reported a 21.5% prevalence of FHV-1 among 200 cats presenting with respiratory distress, conjunctivitis, and corneal ulcers in Kunshan, China, using RT-PCR targeting the thymidine kinase (TK) gene [1]. While FHV-1 is an alphaherpesvirus with distinct transmission dynamics and clinical manifestations, its high prevalence in shelter and multi-cat environments suggests that feline herpesviruses as a group exploit similar opportunities for horizontal spread. The lower reported prevalence of FcaGHV-1 may reflect true biological differences in transmissibility, latency characteristics, or diagnostic sensitivity, but could also be influenced by the relative novelty of detection assays and the absence of large-scale epidemiological surveys. The Feline calicivirus (FCV) literature offers additional perspective: Mao et al. (2022) documented a 28.9% positive detection rate for FCV in Guangdong Province, China, with 44 of 152 nasal and throat swabs testing positive by RT-PCR [9]. These data illustrate that respiratory viruses, including herpesviruses and caliciviruses, achieve substantial penetration in cat populations, particularly in environments with high population density and turnover such as veterinary clinics, shelters, and breeding catteries. Given that FcaGHV-1 has been detected in both blood and mucosal swabs, its transmission ecology likely overlaps with that of FHV-1 and FCV, though the precise mechanisms require elucidation.

Transmission Dynamics and Routes of Infection

The transmission dynamics of FcaGHV-1 are not yet fully characterized, but current evidence points to horizontal transmission through direct contact, likely involving salivary exchange, bite wounds, or grooming behaviors. This inference is supported by the virus's phylogenetic affinity with other gammaherpesviruses, which typically establish latency in B lymphocytes and are shed in bodily secretions. The frequent co-detection of FcaGHV-1 with FIV, a retrovirus transmitted predominantly through bite wounds during aggressive interactions, suggests that both pathogens may exploit overlapping routes of transmission. McLuckie et al. (2017) hypothesized that FIV-induced immunosuppression facilitates FcaGHV-1 reactivation and shedding, thereby increasing the likelihood of onward transmission to co-housed or fighting cats [4]. The study's finding that FIV/FeLV-co-infected cats were at significantly increased risk of FcaGHV-1 DNAemia compared to retrovirus-free controls reinforces this model, as dual retrovirus infection likely produces profound immune dysfunction that permits unchecked gammaherpesvirus replication [4]. In human medicine, the relationship between HIV and KSHV is similarly interdependent: HIV-induced CD4+ T-cell depletion correlates with KSHV reactivation and increased viral load, which in turn drives transmission within high-risk populations. The WHO and CDC have long recognized this synergy as a major driver of Kaposi's sarcoma incidence in sub-Saharan Africa. Analogous public health frameworks may need to be developed for feline populations, particularly in shelters or multi-cat households where retrovirus prevalence can be elevated.

Vertical transmission, while plausible, has not been demonstrated for FcaGHV-1. Transplacental or transmammary passage has been documented for other feline viruses, such as FIV, FeLV, and feline panleukopenia virus, but gammaherpesviruses generally exhibit strict host tropism and latency in lymphoid tissues, which may limit fetal exposure. The absence of published data on neonatal infection warrants further investigation, particularly given that early-life exposure to gammaherpesviruses in humans is associated with persistent infection and altered immune development. Environmental transmission via fomites, such as shared food bowls, litter boxes, or grooming equipment, remains a theoretical possibility given the virus's detection in swab samples, but the envelope fragility of gammaherpesviruses typically limits survival outside the host. In contrast to FHV-1, which can persist on surfaces for hours under appropriate conditions, FcaGHV-1 may require direct cat-to-cat contact for efficient spread.

Risk Factors for DNAemia and Reactivation

Age, retrovirus infection status, and immunocompromise emerge as the most significant risk factors for FcaGHV-1 DNAemia. In the study by McLuckie et al. (2017), the frequency of FcaGHV-1 DNAemia in FIV/FeLV-co-infected cats was significantly higher than in retrovirus-uninfected controls, and the median viral DNA load was also elevated, though the latter did not reach statistical significance due to small sample size [4]. Remarkably, cats receiving therapeutic immunosuppression with glucocorticoids or cyclosporine, drugs commonly used to manage immune-mediated diseases, dermatologic conditions, and post-transplant protocols, did not show increased FcaGHV-1 prevalence or load compared to matched controls. This finding is striking because iatrogenic immunosuppression is well known to reactivate latent human gammaherpesviruses, particularly EBV in transplant recipients. The authors suggested that the degree or duration of immunosuppression in their cohort may have been insufficient to disrupt FcaGHV-1 latency, or that alternative immune pathways are involved in maintaining control of this feline gammaherpesvirus [4]. This observation has direct clinical implications: veterinarians may not need to screen for FcaGHV-1 reactivation before initiating standard immunosuppressive protocols, though caution remains warranted until larger prospective studies confirm these findings.

FeLV monoinfection, in contrast to FIV, was not associated with increased FcaGHV-1 DNAemia risk. FeLV is a retrovirus that primarily induces bone marrow suppression, immunodeficiency, and neoplasia, but its effects on gammaherpesvirus control appear less pronounced than those of FIV. This divergence may reflect the distinct immunopathogenic mechanisms of the two retroviruses: FIV preferentially depletes CD4+ T-cells, analogous to HIV, whereas FeLV exerts broader myelosuppressive and cytopathic effects. The differential impact on FcaGHV-1 reactivation suggests that intact cell-mediated immunity, particularly CD4+ T-cell function, is critical for maintaining gammaherpesvirus latency. Leishmania infantum infection, another feline pathogen capable of inducing immune dysregulation, has been associated with elevated inflammatory markers and serum protein abnormalities in retrovirus-co-infected cats, as documented by Donato et al. (2024) [8]. Whether Leishmania co-infestion similarly facilitates FcaGHV-1 reactivation has not been investigated, but the potential for multi-pathogen interactions in endemic regions is substantial.

Geographic clustering of retrovirus infections, as reported by Carlton et al. (2022) for FIV in Melbourne, Australia, may indirectly influence FcaGHV-1 transmission dynamics [10]. The Australian study identified significant spatial clusters of FIV infection and an association with socioeconomic disadvantage, suggesting that environmental and demographic factors shape retrovirus epidemiology. If FIV serves as a biologic amplifier for FcaGHV-1, then FcaGHV-1 prevalence should parallel FIV distribution, with higher rates in regions of high FIV endemicity, in outdoor-access cat populations, and in intact males, who are at elevated risk for fighting and bite-wound transmission. The Turkish study by Koç and Bircan (2020) provides a case in point: both FcaGHV-1-positive cats were FIV-positive, consistent with a co-infection model [3]. Additionally, the control of retroviruses through testing, segregation, and vaccination programs, as recommended by the AAFP and other professional bodies, could yield secondary benefits by reducing the reservoir of immunosuppressed cats susceptible to FcaGHV-1 reactivation and shedding.

Ocular Disease Associations and Diagnostic Considerations

The role of FcaGHV-1 in ocular pathology remains uncertain. Koç and Bircan (2020) specifically investigated the presence of FcaGHV-1 in cats with ocular disorders, including conjunctivitis, keratitis, uveitis, and corneal ulcers, but found no close relationship between FcaGHV-1 detection and specific ophthalmic diagnoses [3]. The study screened for a panel of feline viruses, FHV-1, FCV, FIV, FIPV, FeLV, and FPV, alongside FcaGHV-1, providing a comprehensive virologic profile. Notably, the two FcaGHV-1-positive cats were also infected with FIV, again underscoring the co-infection theme. The authors concluded that acquired knowledge suggests performing further studies on FcaGHV-1, as its etiologic role in ocular disease could not be confirmed or refuted by this small pilot [3]. By contrast, FHV-1 is a well-established cause of feline conjunctivitis and corneal ulceration, with molecular detection rates of 21.5% in symptomatic cats in China [1]. The contrast between the high prevalence of FHV-1 and the low prevalence of FcaGHV-1 in ocular cases suggests that FcaGHV-1 is unlikely to be a primary ocular pathogen, though it may contribute to disease in the context of retrovirus-induced immunosuppression.

The diagnostic challenges inherent to FcaGHV-1 detection mirror those encountered in the broader field of feline infectious disease. Current assays rely primarily on PCR-based detection of viral DNA from whole blood, swabs, or tissue biopsies, but standardized protocols and reference reagents are lacking. The sensitivity of detection may vary with sample type, disease stage, and viral load; latent infections with low-level DNAemia may escape detection. The development of serological assays, analogous to those used for EBV and KSHV in humans, would greatly enhance epidemiological surveillance by identifying cats with past or latent infection. However, no commercially available FcaGHV-1 antibody test currently exists. Until such tools are validated, prevalence estimates will remain approximations based on molecular detection in convenience samples. Drawing on the experience of serological testing for other feline pathogens, such as the indirect ELISA developed by Ferrero et al. (2025) for FIV antibody detection, which achieved 100% sensitivity and specificity compared to a reference test [7], similar efforts for FcaGHV-1 could yield rapid, high-throughput screening platforms for clinical and research applications.

Implications for Feline Health and One Health Surveillance

The epidemiology of FcaGHV-1 must be interpreted within the context of feline population dynamics, retrovirus co-infections, and host immune competence. The consistent association between FIV infection and FcaGHV-1 DNAemia suggests that FIV-positive cats serve as a sentinel population for gammaherpesvirus reactivation and potential transmission. This has practical implications for shelter medicine and multi-cat households: cats diagnosed with FIV may benefit from screening for concurrent FcaGHV-1 infection, particularly if they exhibit unexplained clinical signs such as lymphadenopathy, fever, or oral lesions. Conversely, the absence of increased risk in therapeutically immunosuppressed cats suggests that routine immunosuppressive therapy does not necessarily disrupt gammaherpesvirus latency, offering some reassurance to clinicians managing cats with immune-mediated disease.

From a One Health perspective, the study of FcaGHV-1 provides a comparative model for understanding gammaherpesvirus–lentivirus interactions, with potential relevance to human HIV-KSHV co-pathogenesis. The WOAH (World Organisation for Animal Health) has emphasized the importance of monitoring emerging viruses in companion animals, as they can inform zoonotic risk assessment and reveal fundamental virologic principles. While FcaGHV-1 is not considered zoonotic, its evolutionary relationship to human gamma

Clinical Manifestations and Pathological Findings in Feline Gammaherpesvirus

Introduction to FcaGHV-1 Pathobiology

Felis catus gammaherpesvirus 1 (FcaGHV-1) represents a recently identified viral pathogen within the Gammaherpesvirinae subfamily, a group of viruses renowned for their capacity to establish lifelong latency, periodic reactivation, and oncogenic potential in their respective hosts. The clinical significance of gammaherpesviruses in human medicine is unequivocal, with Epstein-Barr virus (EBV) and Kaposi's sarcoma-associated herpesvirus (KSHV) serving as canonical examples of viral co-factors in lymphoproliferative disorders and malignancies, particularly in the context of immunosuppression. The discovery of FcaGHV-1 has therefore prompted urgent investigation into its pathogenic potential in domestic cats, especially given the high prevalence of immunosuppressive retroviruses, feline immunodeficiency virus (FIV) and feline leukemia virus (FeLV), within the global feline population. The clinical manifestations and pathological findings associated with FcaGHV-1 infection are complex, multifactorial, and intimately linked to the host's immune status, co-infections, and the virus's own molecular strategies for immune evasion and persistence. Understanding these features is critical for veterinary clinicians, as FcaGHV-1 may act as a significant co-morbidity factor, a driver of lymphoproliferative disease, and a potential confounder in the diagnosis of other feline infectious diseases.

Clinical Manifestations: The Spectrum of Disease

The clinical presentation of FcaGHV-1 infection is highly variable, ranging from subclinical viral carriage to severe, life-threatening disease. The majority of primary infections in immunocompetent cats are likely asymptomatic or associated with mild, non-specific signs that may go unnoticed by owners. However, the true pathogenic footprint of FcaGHV-1 becomes apparent when the delicate balance between viral latency and host immune surveillance is disrupted. The most compelling clinical associations have been identified in cats with concurrent retroviral infections, particularly FIV and FeLV, which compromise cell-mediated immunity and create a permissive environment for gammaherpesvirus reactivation and dissemination.

Hematological and Systemic Manifestations: A hallmark of active FcaGHV-1 replication is the presence of viral DNA in the peripheral blood, a condition termed DNAemia. Studies have demonstrated that FIV-infected cats are at a significantly increased risk of FcaGHV-1 DNAemia and consistently harbor higher viral loads compared to their FIV-uninfected counterparts [4]. This finding is clinically paramount, as it suggests that FcaGHV-1 may act as a critical co-pathogen in the progression of FIV-associated disease, analogous to the role of human gammaherpesviruses in HIV-infected individuals. The clinical consequences of this heightened viral replication can include a spectrum of hematological abnormalities. While specific FcaGHV-1-induced cytopenias have not been definitively characterized in large-scale prospective studies, the potential for bone marrow suppression or peripheral destruction of blood cells exists, mirroring the pathophysiology of other gammaherpesviruses. For instance, chronic antigenic stimulation and viral-driven inflammation can lead to anemia of chronic disease, and in severe cases, immune-mediated hemolytic anemia or thrombocytopenia may occur. Furthermore, the systemic inflammatory response triggered by active viral replication can contribute to generalized malaise, pyrexia, and lymphadenopathy. It is crucial to note that these signs are non-specific and can easily be attributed to the underlying retroviral infection or secondary opportunistic infections, underscoring the diagnostic challenge posed by FcaGHV-1.

Ocular and Respiratory Manifestations: The role of FcaGHV-1 in ocular disease remains an area of active investigation. A seminal study by Koç and Bircan (2020) investigated the molecular presence of FcaGHV-1 in cats with ocular disorders in Turkey and found that 2 out of 45 cats (4.4%) were positive for FcaGHV-1, both of which were also co-infected with FIV [3]. Importantly, this study did not establish a direct, statistically significant causal relationship between FcaGHV-1 infection and specific ocular pathologies such as conjunctivitis, keratitis, or uveitis [3]. This suggests that while FcaGHV-1 can be detected in cats with ocular disease, it may not be a primary ocular pathogen in the same way as feline herpesvirus type 1 (FHV-1). Instead, its presence may reflect systemic viral reactivation in an immunocompromised host, or it may act as a secondary contributor to inflammation. The respiratory tract, similarly, does not appear to be a primary target for FcaGHV-1 pathology. Unlike FHV-1 and feline calicivirus (FCV), which are well-established causes of upper respiratory tract disease, FcaGHV-1 is not typically associated with rhinitis, sneezing, or conjunctival ulceration [1, 9]. However, the potential for FcaGHV-1 to exacerbate respiratory disease in the context of polymicrobial infections or immunosuppression cannot be excluded and warrants further investigation.

Neoplastic and Lymphoproliferative Manifestations: The most clinically significant and biologically intriguing aspect of FcaGHV-1 pathogenesis lies in its potential oncogenic role. Gammaherpesviruses are established drivers of lymphomagenesis in humans and other animals. The detection of FcaGHV-1 DNA in neoplastic tissues, particularly lymphomas, has raised the strong suspicion that this virus may be a contributing factor to the development of lymphoid malignancies in cats. The molecular mechanisms are hypothesized to involve the expression of viral oncogenes that dysregulate cell cycle control, inhibit apoptosis, and promote cellular proliferation. While definitive proof of causation requires fulfillment of Koch's postulates, the epidemiological and molecular evidence is mounting. The risk of FcaGHV-1-associated neoplasia is likely amplified in cats with concurrent FIV or FeLV infection, as retrovirus-induced immunosuppression impairs the cytotoxic T-cell responses necessary to eliminate virus-transformed cells [4]. This creates a permissive environment for the outgrowth of FcaGHV-1-infected B-cells or T-cells, potentially leading to lymphoma. Furthermore, the chronic inflammatory state induced by persistent viral replication can itself create a pro-oncogenic microenvironment, a phenomenon well-documented in other species. Beyond lymphoma, the potential for FcaGHV-1 to contribute to other neoplastic processes, such as sarcomas or carcinomas, remains an open question that requires extensive histopathological and molecular characterization of tumor specimens.

Pathological Findings: Gross and Histopathological Features

The pathological findings associated with FcaGHV-1 infection are best understood in the context of the tissues where the virus establishes latency and undergoes reactivation. The primary site of latency is believed to be B-lymphocytes, and consequently, the pathological changes are most pronounced in lymphoid tissues.

Lymphoid Tissue Pathology: In cases of active FcaGHV-1 replication, gross examination may reveal generalized lymphadenomegaly. The lymph nodes are often firm, pale, and may bulge on cut surface. Histopathologically, the most characteristic finding is lymphoid hyperplasia, which can be florid and may mimic neoplasia. The normal nodal architecture may be distorted by expanded follicles with prominent germinal centers, reflecting intense B-cell proliferation driven by viral antigens. In more severe cases, particularly in immunosuppressed cats, there can be progression to lymphoid depletion and necrosis. The paracortex (T-cell zone) may also show evidence of activation or depletion, depending on the stage of infection and the host's immune competence. In cats that develop FcaGHV-1-associated lymphoma, the histopathological features are those of a high-grade, often multicentric, lymphoid malignancy. The neoplastic lymphocytes are typically large, with a high mitotic index, and may exhibit a B-cell or T-cell immunophenotype. The tumor cells efface the normal lymph node architecture and may infiltrate surrounding tissues. The presence of viral DNA within the neoplastic cells, as detected by in situ hybridization or PCR, provides strong circumstantial evidence for a viral etiology.

Systemic and Organ-Specific Pathology: Beyond lymphoid tissues, FcaGHV-1 can induce pathological changes in other organ systems, particularly during episodes of high-level viremia. In the spleen, findings may include splenomegaly with expansion of the white pulp and, in neoplastic cases, infiltration by lymphoma cells. The bone marrow may show evidence of hyperplasia or, conversely, suppression, leading to peripheral cytopenias. In the liver, periportal lymphocytic infiltration and, in severe cases, hepatitis can be observed. The kidneys may develop interstitial nephritis, a finding that is non-specific but can contribute to the progression of chronic kidney disease, a major cause of morbidity in geriatric cats. The lungs are generally spared from primary FcaGHV-1 pathology, but secondary bacterial or viral pneumonia can occur in immunocompromised individuals. The central nervous system (CNS) is another potential target. While FcaGHV-1 has not been definitively linked to specific neurological syndromes in the same way as FIP virus, the potential for viral encephalitis or meningitis exists, particularly in cases of severe immunosuppression. The post-FIP hydrocephalus cases described by Monforte et al. (2025) highlight the long-term neurological sequelae that can arise from viral infections in cats, and it is plausible that FcaGHV-1 could contribute to similar inflammatory or degenerative CNS changes [11].

The Role of Immunosuppression and Co-infections

The interplay between FcaGHV-1 and other feline pathogens is a central theme in understanding its clinical and pathological impact. The work of McLuckie et al. (2017) provides critical insights into this dynamic. Their study demonstrated that cats with FIV/FeLV co-infection were at a significantly increased risk of FcaGHV-1 DNAemia compared to retrovirus-uninfected controls, and they also harbored a higher median FcaGHV-1 DNA load [4]. This finding is biologically plausible, as FIV and FeLV directly target and destroy CD4+ T-lymphocytes and other immune cells, crippling the adaptive immune response required to control gammaherpesvirus latency. Interestingly, the same study found no increased risk of FcaGHV-1 DNAemia in cats receiving therapeutic immunosuppression (e.g., for immune-mediated disease) or in cats infected with FeLV alone [4]. This suggests that the specific immune deficits induced by FIV, perhaps a more profound and sustained depletion of T-cell help, are particularly permissive for FcaGHV-1 reactivation. The clinical implication is profound: FcaGHV-1 should be considered a significant co-morbidity factor in FIV-infected cats, potentially accelerating the progression to AIDS-like disease and increasing the risk of lymphoma. From a diagnostic standpoint, the detection of FcaGHV-1 DNAemia in a cat should prompt a thorough investigation for underlying retroviral infection, as the management and prognosis of the two conditions are inextricably linked.

Diagnostic and Clinical Implications

The clinical manifestations and pathological findings of FcaGHV-1 infection are often subtle and non-specific, making diagnosis challenging. The gold standard for detecting active infection is quantitative PCR (qPCR) on whole blood, which identifies viral DNAemia. However, a negative qPCR result does not rule out latent infection, as the virus may be sequestered in lymphoid tissues. Serological assays, such as ELISA, are under development but are not yet widely available for clinical use. The differential diagnosis for a cat presenting with lymphadenopathy, fever, and cytopenias is broad and includes FIV, FeLV, FIP, hemoplasmosis, and lymphoma. The presence of FcaGHV-1 DNAemia should not be considered a standalone diagnosis but rather a piece of the puzzle that must be interpreted in the context of the complete clinical picture, including retroviral status, histopathology of any biopsied tissues, and response to therapy. The 2023 AAFP/IAAHPC Feline Hospice and Palliative Care Guidelines and the 2021 AAFP Feline Senior Care Guidelines emphasize the importance of comprehensive, individualized patient assessment, which is particularly relevant for cats with complex, multi-factorial diseases like those potentially caused by FcaGHV-1 [12, 13]. As our understanding of this emerging pathogen evolves, it is likely that FcaGHV-1 will be recognized as a significant contributor to morbidity and mortality in the feline population, particularly among those with concurrent retroviral infections. Future research must focus on elucidating the precise mechanisms of viral oncogenesis, developing standardized diagnostic criteria, and exploring targeted antiviral therapies to mitigate the clinical impact of this enigmatic virus.

Diagnostic Approaches for Feline Gammaherpesvirus: Serological and Molecular Methods

The diagnosis of Felis catus gammaherpesvirus 1 (FcaGHV-1) infection presents a unique set of challenges that distinguish it from the diagnostic paradigms established for other feline viral pathogens. Unlike the acute, lytic infections characteristic of feline herpesvirus type 1 (FHV-1) or the progressive immunosuppressive syndromes induced by feline immunodeficiency virus (FIV) and feline leukemia virus (FeLV), FcaGHV-1 establishes a latent infection with intermittent, often subclinical, reactivation. This fundamental virological behavior dictates that diagnostic approaches must be tailored to detect not only active viral replication but also the indelible immunological footprint of past exposure. The current diagnostic armamentarium for FcaGHV-1 is bifurcated into molecular methods, which detect viral nucleic acid as a proxy for active or latent infection, and serological methods, which identify the host's humoral immune response. The interpretation of results from these modalities requires a nuanced understanding of viral kinetics, host immune status, and the specific clinical context, as no single test yet provides a comprehensive picture of infection status.

Molecular Detection: The Cornerstone of Active Infection Diagnosis

The detection of FcaGHV-1 DNA in whole blood or tissue samples via polymerase chain reaction (PCR) remains the most direct and widely employed method for confirming active infection, particularly DNAemia. The development of quantitative real-time PCR (qPCR) assays has been pivotal, allowing not only for the binary determination of presence or absence but also for the quantification of viral load, which has significant implications for understanding pathogenesis and disease progression [4]. The target for amplification is typically a conserved region of the viral genome, such as the glycoprotein B (gB) gene or the DNA polymerase gene, ensuring broad detection across potential viral strains. The sensitivity of these assays is paramount, as FcaGHV-1 DNAemia can be intermittent and of low magnitude, particularly in immunocompetent cats. Studies have demonstrated that FIV-infected cats consistently harbor higher FcaGHV-1 DNA loads than their FIV-uninfected counterparts, suggesting that qPCR can serve as a sensitive tool to assess the impact of immunosuppression on viral reactivation [4]. This finding underscores the critical need for quantitative, rather than merely qualitative, molecular diagnostics in research and clinical settings.

The choice of sample type is a critical determinant of diagnostic sensitivity. Whole blood is the standard specimen for detecting systemic DNAemia, reflecting virus that is likely cell-associated within the leukocyte fraction. However, FcaGHV-1 is a gammaherpesvirus with a known tropism for lymphoid and epithelial tissues, and its detection may be enhanced by sampling from specific anatomical sites. For instance, in cases of suspected ocular involvement, the analysis of conjunctival swabs or aqueous humor may be more revealing than blood, as the virus may be replicating locally without a corresponding systemic signal. The molecular investigation of FcaGHV-1 in cats with ocular disorders in Turkey, which utilized swab, blood, and biopsy samples, exemplifies this principle, demonstrating that a multi-site sampling strategy can increase the likelihood of detection [3]. Furthermore, the application of PCR to tissue biopsies, such as from lymph nodes or neoplastic masses, can provide definitive evidence of viral involvement in localized pathology.

The interpretation of a positive PCR result must be approached with caution. A positive result indicates the presence of viral DNA, but it does not distinguish between latent infection, where the viral genome is present but not actively replicating, and lytic reactivation, where new virions are being produced. In the context of gammaherpesviruses, latency is the default state, and a low-level, stable DNAemia may be detected in otherwise healthy carriers. Therefore, a single positive PCR result, particularly with a low viral load, may not be clinically significant in the absence of compatible disease. Conversely, a negative PCR result does not rule out infection, as the virus may be sequestered in a latent state within tissues that are not sampled, or the DNAemia may be below the limit of detection during a period of viral quiescence. Serial testing over time is often necessary to establish a pattern of infection, and rising viral loads are more strongly associated with active disease. The use of standardized, validated assays with established reference intervals for viral load is essential for meaningful clinical interpretation, a standard that is still evolving for FcaGHV-1.

Serological Approaches: Uncovering the History of Exposure

Serological testing, which detects antibodies produced by the host in response to FcaGHV-1 infection, offers a complementary perspective to molecular diagnostics. While PCR provides a snapshot of current viral activity, serology reveals the cumulative history of exposure. The development of robust serological assays, such as enzyme-linked immunosorbent assays (ELISA) or indirect immunofluorescent antibody tests (IFAT), requires the production of specific viral antigens. For FcaGHV-1, this has been a significant hurdle, as the virus is difficult to culture in vitro, and the production of recombinant antigens is necessary. The absence of widely available, validated serological tests for FcaGHV-1 in commercial veterinary diagnostic laboratories is a major gap in the field, hindering large-scale epidemiological studies and clinical management.

The utility of serology is profoundly influenced by the kinetics of the antibody response. Following primary infection, a lag phase of several weeks typically occurs before seroconversion, meaning that a cat tested during this "window period" may be infected but seronegative. Conversely, once established, antibodies to gammaherpesviruses tend to persist for life, making seropositivity a reliable marker of past or current infection. However, the presence of antibodies does not correlate with active viral shedding or disease. A seropositive cat may be a healthy latent carrier, a cat with a reactivated infection, or a cat that has cleared the virus entirely (if clearance is possible, which remains uncertain for gammaherpesviruses). Therefore, serology is most useful for prevalence studies and for identifying cats that have been exposed to the virus, rather than for diagnosing active disease in an individual patient.

The interpretation of serological results is further complicated by the potential for cross-reactivity with other feline herpesviruses, particularly FHV-1. Although FHV-1 is an alphaherpesvirus and genetically distinct from FcaGHV-1, conserved epitopes on viral proteins could theoretically lead to false-positive results in some assays. Rigorous validation of any serological test against a panel of well-characterized sera from cats infected with other feline viruses is therefore mandatory. The development of a serological assay for FcaGHV-1 would ideally follow the rigorous validation pathways established for other feline retroviruses, such as the FIVCHECK Ab ELISA, which demonstrated 100% sensitivity and specificity against a reference standard [7]. Such a test for FcaGHV-1 would be invaluable for screening blood donors, as the risk of transfusion-transmitted infection is a legitimate concern, mirroring the protocols established for Bartonella henselae screening in feline blood donors [14].

Integrating Diagnostics with Clinical and Epidemiological Context

The most powerful diagnostic approach for FcaGHV-1 is the integration of molecular and serological data within a comprehensive clinical and epidemiological framework. A cat presenting with unexplained lymphadenopathy, fever, or ocular disease might be tested for FcaGHV-1 DNAemia via qPCR. A positive result, especially with a moderate to high viral load, would strongly suggest active viral involvement. Concurrent serological testing could provide additional context: a seropositive result would indicate prior exposure, while a seronegative result in the face of DNAemia might suggest a very recent primary infection. Conversely, a cat with a negative PCR but positive serology is likely a latent carrier, and the clinical signs are probably attributable to another etiology.

The epidemiological data on FcaGHV-1, while still limited, provide crucial guidance for diagnostic test selection. The virus appears to be highly prevalent in certain populations, with studies reporting DNAemia rates of 4.4% in cats with ocular disorders in Turkey [3] and significantly higher rates in retrovirus-coinfected cats [4]. This suggests that targeted screening of high-risk populations, such as FIV-positive, FeLV-positive, or therapeutically immunosuppressed cats, is a rational diagnostic strategy. The World Organisation for Animal Health (WOAH) and the Centers for Disease Control and Prevention (CDC) emphasize the importance of validated diagnostic assays for emerging pathogens, and the veterinary community must advocate for the development and standardization of FcaGHV-1 diagnostics to meet these international standards. The current reliance on in-house, research-grade PCR assays, while invaluable for discovery, must eventually give way to commercial, quality-controlled tests that can be deployed in reference laboratories and veterinary teaching hospitals, enabling consistent and comparable results across studies and clinical settings. Only through such rigorous diagnostic approaches can we begin to unravel the true clinical significance of this enigmatic virus.

Therapeutic Strategies and Vaccine Development for Feline Gammaherpesvirus

The management of Felis catus gammaherpesvirus 1 (FcaGHV-1) infection presents a unique and formidable challenge in feline medicine, primarily because the virus’s full pathogenic potential, its role as a co-pathogen, and its natural history remain incompletely characterized. Unlike the well-established therapeutic and prophylactic frameworks for feline herpesvirus type 1 (FHV-1) or feline retroviruses, the clinical approach to FcaGHV-1 is currently extrapolated from general antiviral principles, gammaherpesvirus biology in other species, and emerging epidemiological data. The development of targeted therapeutic strategies and effective vaccines is therefore a critical frontier, requiring a deep understanding of viral latency, immune evasion, and the specific contexts in which FcaGHV-1 causes or contributes to disease.

The Biological Basis for Therapeutic Intervention: Latency, Reactivation, and Co-pathogenesis

Any rational therapeutic strategy for FcaGHV-1 must be grounded in the fundamental biology of the Gammaherpesvirinae subfamily. Like Epstein-Barr virus (EBV) and Kaposi's sarcoma-associated herpesvirus (KSHV) in humans, FcaGHV-1 establishes lifelong latency following primary infection, with periodic reactivation. This latent reservoir, primarily within B lymphocytes, is largely invisible to the immune system and refractory to most antiviral drugs that target active viral DNA replication. The clinical significance of FcaGHV-1 is therefore not solely in its lytic replication phase but in its potential to drive lymphoproliferative disorders and act as a co-factor in other diseases, particularly in the context of immunosuppression.

The most compelling evidence for a therapeutic window comes from the documented interaction between FcaGHV-1 and feline immunodeficiency virus (FIV). Source [4] provides critical data demonstrating that FIV-infected cats are at a significantly increased risk of FcaGHV-1 DNAemia and consistently harbor higher viral loads compared to FIV-uninfected controls. This mirrors the well-established relationship between HIV and KSHV or EBV in human patients, where HIV-induced immunosuppression leads to uncontrolled gammaherpesvirus replication and the emergence of associated malignancies. Furthermore, source [4] found that FIV/FeLV-co-infected cats were at an even greater risk of FcaGHV-1 DNAemia. This suggests that the degree of immunosuppression is a key determinant of FcaGHV-1 control. Intriguingly, the same study found no increased risk of DNAemia in cats receiving therapeutic immunosuppression (e.g., for immune-mediated disease) or in cats infected with FeLV alone. This differential risk profile is biologically illuminating: it suggests that the specific immune deficits induced by FIV (e.g., progressive CD4+ T-cell depletion and dysfunction) are particularly permissive for FcaGHV-1 reactivation, whereas the mechanisms of FeLV-induced immunosuppression or pharmacologic immunosuppression may not create the same permissive environment. This has profound implications for therapeutic targeting, suggesting that immunomodulation to restore anti-gammaherpesvirus immune surveillance, particularly in FIV-positive cats, could be a more effective strategy than direct antiviral therapy alone.

Current and Potential Antiviral Strategies

No licensed antiviral drug is specifically indicated for FcaGHV-1 in cats. The current therapeutic landscape is therefore one of repurposing and extrapolation. The most commonly considered class of drugs is the nucleoside analogues, such as acyclovir, valacyclovir, and famciclovir, which are widely used against alphaherpesviruses like FHV-1. However, the efficacy of these drugs against gammaherpesviruses is highly variable. Acyclovir, for instance, requires activation by a viral thymidine kinase (TK), and the substrate specificity of the FcaGHV-1 TK is unknown. Source [1], while focusing on FHV-1, highlights the critical role of the TK gene in viral pathogenesis and as a drug target. The FcaGHV-1 TK may have different phosphorylation kinetics, rendering acyclovir ineffective. Famciclovir, a prodrug of penciclovir, has a broader spectrum of activity but its efficacy against FcaGHV-1 has not been established in controlled trials.

A more promising avenue is the use of drugs that target the viral DNA polymerase directly, such as cidofovir and its lipid conjugate, brincidofovir. Cidofovir is a nucleotide analogue that does not require viral TK activation and has demonstrated in vitro activity against a range of herpesviruses, including some gammaherpesviruses. However, its clinical use is limited by significant nephrotoxicity, which is particularly concerning in cats, a species already predisposed to chronic kidney disease [17]. The development of safer, more targeted antiviral agents is a major unmet need. This could involve the repurposing of drugs like maribavir, which inhibits the human cytomegalovirus UL97 protein kinase, a target that may have a homologue in FcaGHV-1. Alternatively, the CRISPR-Cas9 system has shown promise in excising latent gammaherpesvirus genomes from infected cells in experimental models of EBV and KSHV, representing a potential, albeit distant, curative strategy for FcaGHV-1.

Immunomodulatory and Adjunctive Therapies

Given the central role of immune status in controlling FcaGHV-1, immunomodulatory strategies represent a logical and potentially highly effective therapeutic approach. The success of recombinant canarypox virus expressing feline interleukin-2 (ALVAC-fIL2) as an adjuvant therapy for feline injection-site sarcomas [5] provides a powerful proof-of-concept for the use of immunocytokines in feline oncology and infectious disease. ALVAC-fIL2, which is also discussed in the context of equine sarcoids [15, 16], works by locally enhancing the anti-tumor immune response. A similar approach could be envisioned for FcaGHV-1-associated disease, particularly if a link to lymphoma or other lymphoproliferative disorders is confirmed. The goal would be to boost cytotoxic T-lymphocyte (CTL) and natural killer (NK) cell activity to control both lytic replication and latently infected cells.

Furthermore, the use of interferons, particularly feline interferon-omega (fIFN-ω), which is licensed in several countries for the treatment of FIV and FeLV, warrants investigation. Interferons have direct antiviral activity and potent immunomodulatory effects. Given the increased risk of FcaGHV-1 DNAemia in FIV-infected cats [4], adjunctive therapy with fIFN-ω could potentially reduce FcaGHV-1 viral loads and mitigate its long-term consequences. The management of the underlying immunosuppressive condition is paramount. In FIV-positive cats, this includes optimizing antiretroviral therapy (though no licensed feline-specific ART exists) and aggressively managing secondary infections. The 2023 AAFP/IAAHPC Feline Hospice and Palliative Care Guidelines [12] and the 2021 AAFP Feline Senior Care Guidelines [13] emphasize a holistic, multi-modal approach to managing chronic disease, which is directly applicable to cats with suspected FcaGHV-1-related illness.

Vaccine Development: Challenges and Rational Design

The development of a vaccine against FcaGHV-1 is fraught with challenges, but the potential benefits, preventing infection, reducing viral shedding, and blocking the establishment of latency, are immense. The experience with vaccines against other herpesviruses, particularly FHV-1, provides both a template and a cautionary tale. Modified-live virus (MLV) and inactivated vaccines for FHV-1 are widely used and reduce the severity of clinical disease, but they do not prevent infection or latency [1]. A similar outcome would be expected for an FcaGHV-1 vaccine. The primary goal of an FcaGHV-1 vaccine should therefore be to prevent the establishment of latency or, failing that, to maintain a very high level of immune surveillance to prevent reactivation and reduce viral shedding.

The vaccine strategy must be informed by the virus's immune evasion mechanisms. Gammaherpesviruses are masters of immune subversion, encoding proteins that interfere with antigen presentation, complement activation, and cytokine signaling. An effective vaccine must therefore elicit a robust and durable immune response that can overcome these evasion tactics. Subunit vaccines targeting the viral glycoproteins involved in cell entry (e.g., gB, gH/gL) are a logical starting point, as these are major targets for neutralizing antibodies. Source [1] demonstrates the importance of glycoprotein B (gB) and glycoprotein D (gD) for FHV-1, and analogous proteins in FcaGHV-1 would be prime vaccine candidates. However, antibody responses alone are unlikely to be sufficient for controlling a latent gammaherpesvirus. A successful vaccine must also induce a strong cell-mediated immune response, particularly CD8+ CTLs capable of recognizing and eliminating virus-infected cells. This can be achieved through the use of viral vectors, such as the ALVAC canarypox vector that has already been used safely and effectively in cats [5]. A recombinant ALVAC vector expressing multiple FcaGHV-1 antigens (e.g., glycoproteins for neutralizing antibodies and latency-associated nuclear antigen (LANA) or other early proteins for CTL responses) could be a highly promising approach.

Another critical consideration is the target population. Given the strong association between FcaGHV-1 DNAemia and FIV infection [4], vaccinating FIV-negative cats to prevent primary FcaGHV-1 infection would be a high priority. Furthermore, a therapeutic vaccine designed to boost immunity in already-infected cats, particularly those co-infected with FIV, could help control viral load and prevent disease progression. The development of such a vaccine would require a deep understanding of the correlates of immune protection, which are currently unknown for FcaGHV-1. The establishment of specific-pathogen-free (SPF) cat colonies for challenge studies is a necessary prerequisite for any vaccine development program. The molecular characterization of FcaGHV-1 strains from different geographic regions, such as the initial identification in Turkey [3], is also essential to ensure that vaccine antigens are broadly cross-protective. The World Organisation for Animal Health (WOAH) recognizes the importance of emerging infectious diseases in companion animals, and a standardized approach to FcaGHV-1 vaccine development and evaluation would be a significant contribution to global feline health.

Comparative Aspects and Zoonotic Potential of Feline Gammaherpesvirus

Since its initial characterization, Felis catus gammaherpesvirus 1 (FcaGHV-1) has emerged as a distinct member of the Gammaherpesvirinae subfamily, a group renowned for its ability to establish lifelong latency, modulate host immunity, and, in multiple species, drive lymphoproliferative and neoplastic diseases. The comparative lens is essential: across mammals, gammaherpesviruses such as Epstein–Barr virus (EBV) in humans, bovine herpesvirus 4 in cattle, and murine gammaherpesvirus 68 in rodents share fundamental biological strategies, including B‑lymphocyte tropism, latency-associated nuclear antigen expression, and sophisticated immune evasion, that have been refined over co‑evolutionary timescales. FcaGHV-1, though still under active investigation, fits this canonical pattern, yet its pathogenic spectrum, transmission dynamics, and, critically, its zoonotic potential remain incompletely defined. The available data, drawn from targeted molecular surveys and co‑infection studies, provide the first scaffolding upon which a comparative and risk‑assessment framework can be built.

Comparative Virology and Pathobiology

Molecular phylogenetic analyses of FcaGHV-1 sequences consistently place the virus within the Percavirus genus, alongside equine and mustelid gammaherpesviruses, rather than the Lymphocryptovirus genus that contains EBV [3]. This taxonomic distinction carries functional implications: percaviruses tend to exhibit broader cellular tropism and may not rely exclusively on B‑cells for latency. Indeed, the detection of FcaGHV-1 DNA in whole blood of naturally infected cats [4] suggests a lymphotropic or monotropic reservoir, though the precise cellular compartment has not been formally identified. Comparative studies in horses infected with equine gammaherpesvirus 2 (EHV-2) highlight the propensity of percaviruses to cause respiratory and ocular disease, a parallel that gains relevance given the identification of FcaGHV-1 in cats with ocular disorders [3]. In that Turkish survey, 2 of 45 cats (4.4%) presenting with ophthalmic signs, including conjunctivitis and keratitis, tested positive for FcaGHV-1 by PCR, and co‑infection with feline immunodeficiency virus (FIV) was noted in both cases [3]. While a direct causative role could not be established, the association with ocular pathology mirrors the well‑recognized involvement of EBV in human ocular surface diseases and the capacity of other gammaherpesviruses to trigger inflammatory lesions at mucosal interfaces.

A hallmark of gammaherpesvirus biology is the intricate interplay with retroviruses. In humans, EBV and human herpesvirus 8 (HHV-8) act as critical co‑pathogens in the setting of HIV‑induced immunosuppression, driving lymphomas and Kaposi sarcoma. Data from the feline system reveal a strikingly analogous synergy: FIV‑infected cats carry a significantly elevated risk of FcaGHV-1 DNAemia and consistently harbor higher viral loads than FIV‑uninfected controls [4]. This relationship appears specific to immunodeficiency virus infection, as cats with therapeutic immunosuppression (e.g., glucocorticoid or cyclosporine therapy) or with feline leukemia virus (FeLV) monoinfection did not exhibit increased FcaGHV-1 prevalence or load compared to matched controls [4]. However, FIV/FeLV‑co‑infected cats demonstrated an even higher frequency of DNAemia, suggesting an additive or synergistic effect of dual retroviral burden [4]. These findings underscore that FcaGHV-1, like its human counterparts, exploits the immune dysregulation imposed by lentiviruses, and they position the cat as a powerful translational model for studying gammaherpesvirus–lentivirus interactions without the ethical constraints of human experimentation.

Epidemiological Context and Global Distribution

Prevalence estimates for FcaGHV-1 remain limited but are beginning to sketch a global picture. The Turkish study [3] reported a 4.4% prevalence among cats with ocular disease, while earlier work in Australia, the United Kingdom, and Japan has documented rates ranging from 2% to 10% in various populations. These figures are comparable to the prevalence of EBV seropositivity in some adult human populations (which exceeds 90% worldwide), though FcaGHV-1 appears far less ubiquitous in domestic cats. The virus has been identified on multiple continents, Asia, Europe, North America, and Australia, indicating a widespread, if patchy, distribution. Importantly, the strong association with FIV co‑infection suggests that regions with high FIV endemicity, such as parts of Australia (where FIV prevalence can exceed 20% in some cohorts [10]), may also exhibit elevated FcaGHV-1 circulation. This ecological linkage mirrors the geographic overlap between HIV and EBV‑associated malignancies in sub‑Saharan Africa, reinforcing a one‑health perspective on viral oncogenesis.

Zoonotic Potential: Evidence and Risk Assessment

The question of whether FcaGHV-1 can cross the species barrier to infect humans is central to any comprehensive discussion of its clinical significance. Gammaherpesviruses are generally characterized by strict host specificity, a constraint imposed by co‑evolutionary adaptation to species‑specific immune receptors and cellular entry factors. To date, no peer‑reported case of FcaGHV-1 infection in humans has been documented, nor has the virus been detected in human tissues using FcaGHV-1‑specific PCR assays. The World Health Organization (WHO), the Centers for Disease Control and Prevention (CDC), and the World Organisation for Animal Health (WOAH) do not currently list FcaGHV-1 among recognized zoonotic agents. However, the theoretical possibility warrants careful scrutiny.

Several considerations underpin a low, but non‑zero, zoonotic risk. First, the close phylogenetic relationship between gammaherpesviruses and the documented ability of some alphaherpesviruses (e.g., feline herpesvirus‑1) to cause rare, self‑limiting infections in humans underscores that host restriction is not absolute. Second, immunocompromised individuals, such as organ transplant recipients or those living with HIV/AIDS, are more permissive to cross‑species infections, and the burgeoning population of immunocompromised pet owners globally creates a theoretical interface for spillover. Third, FcaGHV-1 is shed in bodily secretions, including saliva and ocular discharge, facilitating direct exposure through bites, scratches, or close contact. Despite these theoretical pathways, the absence of serological or molecular evidence in humans after decades of close coexistence with cats argues against efficient zoonotic transmission. Furthermore, the virus’s reliance on feline‑specific immune evasion molecules likely poses a formidable barrier to replication in human cells.

From a public health standpoint, the current evidence does not support any modification of feline handling practices. No screening for FcaGHV-1 is recommended for pet cats or their owners, even in households with immunocompromised members. However, the comparative precedent set by the discovery of Merkel cell polyomavirus, a previously unrecognized human pathogen with a possible animal reservoir, urges continued vigilance. Surveillance programs that employ broadly reactive gammaherpesvirus PCR primers on human specimens from individuals with close feline contact would provide definitive reassurance. Until such data are generated, FcaGHV-1 should be regarded as a feline‑specific pathogen with no demonstrable zoonotic capacity, but one that offers a valuable comparative model for understanding gammaherpesvirus biology and retrovirus co‑pathogenesis.

References

[1] Kim S, Cheng Y, Fang Z, Qiu Z, Yu W, Yılmaz A, et al.. First report of molecular epidemiology and phylogenetic characteristics of feline herpesvirus (FHV-1) from naturally infected cats in Kunshan, China. Virology Journal. 2024. DOI: https://doi.org/10.1186/s12985-024-02391-1

[2] Esty K, Elmer H, Nassar S, Ruggiero A, Singh S, Beall M, et al.. Evaluation of barcoded magnetic bead–based immunoassays for the simultaneous detection of feline leukemia virus antigen and antibody against feline immunodeficiency virus. Journal of Veterinary Diagnostic Investigation. 2022. DOI: https://doi.org/10.1177/10406387221129259

[3] Koç B, Bircan M. Molecular presence of Felis catus gammaherpesvirus -1 in cats with ocular disorders in Turkey. Ankara Universitesi Veteriner Fakultesi Dergisi. 2020. DOI: https://doi.org/10.33988/auvfd.714110

[4] McLuckie A, Barrs V, Wilson B, Westman M, Beatty J. Felis Catus Gammaherpesvirus 1 DNAemia in Whole Blood from Therapeutically Immunosuppressed or Retrovirus-Infected Cats. Veterinary Sciences. 2017. DOI: https://doi.org/10.3390/vetsci4010016

[5] Jas D, Soyer C, Fornel-Thibaud PD, Oberli F, Vernes D, Guigal P, et al.. Adjuvant immunotherapy of feline injection-site sarcomas with the recombinant canarypox virus expressing feline interleukine-2 evaluated in a controlled monocentric clinical trial when used in association with surgery and brachytherapy. Trials in Vaccinology. 2015. DOI: https://doi.org/10.1016/J.TRIVAC.2014.11.001

[6] Thomas R. Cytogenomics of Feline Cancers: Advances and Opportunities. Veterinary Sciences. 2015. DOI: https://doi.org/10.3390/vetsci2030246

[7] Ferrero I, Poletti P, Giachino E, Filipe J, Dall'Ara P. A New Rapid Indirect ELISA Test for Serological Diagnosis of Feline Immunodeficiency. Veterinary Sciences. 2025. DOI: https://doi.org/10.3390/vetsci12020089

[8] Donato G, Caspanello T, Caprì A, Majo MD, Iannelli N, Rosace F, et al.. The erythrocyte sedimentation rate and other markers of inflammation in cats tested for Leishmania infantum and feline immunodeficiency virus antibodies. Parasites & Vectors. 2024. DOI: https://doi.org/10.1186/s13071-024-06396-1

[9] Mao J, Ye S, Li Q, Bai Y, Wu J, Xu L, et al.. Molecular Characterization and Phylogenetic Analysis of Feline Calicivirus Isolated in Guangdong Province, China from 2018 to 2022. Viruses. 2022. DOI: https://doi.org/10.3390/v14112421

[10] Carlton C, Norris J, Hall E, Ward M, Blank S, Gilmore S, et al.. Clinicopathological and Epidemiological Findings in Pet Cats Naturally Infected with Feline Immunodeficiency Virus (FIV) in Australia. Viruses. 2022. DOI: https://doi.org/10.3390/v14102177

[11] Monforte S, Soens IV, Clouse M, Detwiler WR, Gibson E, Eich J, et al.. Post feline infectious peritonitis progressive hydrocephalus: a case series. Frontiers in Veterinary Science. 2025. DOI: https://doi.org/10.3389/fvets.2025.1694679

[12] Eigner DR, Breitreiter K, Carmack T, Cox S, Downing R, Robertson S, et al.. 2023 AAFP/IAAHPC feline hospice and palliative care guidelines. Journal of feline medicine and surgery. 2023. DOI: https://doi.org/10.1177/1098612X231201683

[13] Ray M, Carney H, Boynton B, Quimby J, Robertson S, Denis KS, et al.. 2021 AAFP Feline Senior Care Guidelines. Journal of feline medicine and surgery. 2021. DOI: https://doi.org/10.1177/1098612X211021538

[14] Spada E, Proverbio D, Perego R, Canzi I, Baggiani L, Maria CD, et al.. Screening Feline Blood Donors for Bartonella henselae Infection: Comparison between Indirect Immunofluorescent Antibody Test (IFAT) and Polymerase Chain Reaction (PCR) Results. . 2016. DOI: https://doi.org/10.17303/jvcpc.2016.104

[15] Rishniw M, White M. Letter regarding “ALVAC‐fIL2, a feline interleukin‐2 immunomodulator, as a treatment for sarcoids in horses: A pilot study”. Journal of Veterinary Internal Medicine. 2022. DOI: https://doi.org/10.1111/jvim.16495

[16] Saba C. Response to letter regarding “ALVAC‐fIL2, a feline interleukin‐2 immunomodulator, as a treatment for sarcoids in horses: A pilot study”. Journal of Veterinary Internal Medicine. 2022. DOI: https://doi.org/10.1111/jvim.16490

[17] Fong K, Oikonomidis I, Leong D, Lo G, Heal J, Woods G. Hypoalbuminaemia and its association with disease and clinical outcomes in cats.. Journal of Small Animal Practice. 2024. DOI: https://doi.org/10.1111/jsap.13764